How to judge the curative effect of the antineoplastic drug which makes anti-CD4 antibody an active ingredient - National University Corporation Tokyo University

Title:

How to judge the curative effect of the antineoplastic drug which makes anti-CD4 antibody an active ingredient

Document Type and Number:

Japanese Patent JP6274542

Kind Code:

B2

Abstract:

Means that enables monitoring of an anticancer effect of an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint is disclosed. The method for testing a therapeutic effect of a cancer therapy of the present invention is a method for testing a therapeutic effect of an anticancer drug comprising as an effective ingredient an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint, which method comprises investigation of expression of (1) at least one immune checkpoint receptor, (2) CD8, and (3) at least one cell surface molecule selected from the group consisting of CD44 and CD45RO, on T cells using a sample derived from a patient who received the anticancer drug. Induction of a T cell population which is positive for the immune checkpoint molecule (1) and positive for CD8, and which shows high expression of CD44 and/or high expression of CD45RO, indicates that said anticancer drug is producing a therapeutic effect in said patient.

Inventors:

Koji Matsushima
Satoshi Ueba
Satoshi Ito
Shoji Yokochi
Yoshiro Ishiwatari

Application Number:

JP2016562649A

Publication Date:

February 07, 2018

Filing Date:

December 02, 2015

Export Citation:

Click for automatic bibliography generation Help

Assignee:

National University Corporation Tokyo University
idac Theranostics Co., Ltd.

International Classes:

G01N33/68; C12Q1/02; C12Q1/68; G01N33/48; G01N33/49

Domestic Patent References:

JP2012510619A

Foreign References:

WO2014151006A2
WO2014059251A1
WO2010074266A1

Other References:

Beom K. CHOI et al.,Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy,Cancer Research,2007年,Vol.67,p.8891-8899

Attorney, Agent or Firm:

Patent Service Corporation Tanigawa International Patent Office

Previous Patent: Mode synchronous laser, a high-speed optical signal processing device, and a spectrum part light mea...

Next Patent: WORKPIECE CARRIER